Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 2/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637631 | 0.93 | KMT2A (0.72) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL6102836 | 0.90 | CYP19A1 (0.74) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4637678 | 0.86 | KMT2A (0.62) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4638528 | 0.86 | POLB (0.68) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4616156 | 0.86 | CYP19A1 (0.62) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4636998 | 0.85 | KMT2A (0.67) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL6103107 | 0.84 | ALDH1A1 (0.60) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL6102262 | 0.84 | KMT2A (0.62) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4637137 | 0.84 | KMT2A (0.68) | KMT2AALDH1A1CYP19A1POLBLMNA | |
| SCHEMBL4639163 | 0.84 | SFRP1 (0.67) | KMT2AALDH1A1CYP19A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | KMT2A 3832/4885ALDH1A1 1865/4885CYP19A1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.